Skip to main content
SpringerLink
Log in

Cholangiocarcinoma

  • Chapter
  • First Online:
Textbook of Gastrointestinal Oncology

Abstract

Biliary tract cancers (BTCs) are rare gastrointestinal malignancies that involve the liver and biliary tract. Despite their being uncommon, there has been an increase in their incidence, likely due to novel risk factors. In patients who are diagnosed with limited stage disease, treatment entails potential curative treatment options including surgical resection or orthotopic liver transplantation. Unfortunately, the most present with advanced or metastatic disease where treatment is limited and primarily supportive. However, with increasing knowledge about the pathogenesis and genomic variants in BTCs, the development of novel targeted agents can result in improved outcomes, with a shift in the paradigm in how this disease is treated.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cardinale V, Carpino G, Reid L, Gaudio E, Alvaro D. Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity. World J Gastrointest Oncol. 2012;4(5):94–102.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Theise ND, Saxena R, Portmann BC, Thung SN, Yee H, Chiriboga L, et al. The canals of hering and hepatic stem cells in humans. Hepatology. 1999;30(6):1425–33.

    Article  CAS  PubMed  Google Scholar 

  3. Cardinale V, Wang Y, Carpino G, Cui CB, Gatto M, Rossi M, et al. Multipotent stem/progenitor cells in human biliary tree give rise to hepatocytes, cholangiocytes, and pancreatic islets. Hepatology. 2011;54(6):2159–72.

    Article  CAS  PubMed  Google Scholar 

  4. Carpino G, Cardinale V, Onori P, Franchitto A, Berloco PB, Rossi M, et al. Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts: an anatomical in situ study yielding evidence of maturational lineages. J Anat. 2012;220(2):186–99.

    Article  PubMed  Google Scholar 

  5. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology. 2005;128(6):1655–67.

    Article  PubMed  Google Scholar 

  6. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002;2:10.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8(9):512–22.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Charbel H, Al-Kawas FH. Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis. Curr Gastroenterol Rep. 2011;13(2):182–7.

    Article  PubMed  Google Scholar 

  9. Dickson PV, Behrman SW. Distal cholangiocarcinoma. Surg Clin North Am. 2014;94(2):325–42.

    Article  PubMed  Google Scholar 

  10. Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol. 2013;11(1):13–21.e11; quiz e13–14.

    Article  PubMed  Google Scholar 

  11. Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet (London, England). 2014;383(9935):2168–79.

    Article  Google Scholar 

  12. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145(6):1215–29.

    Article  CAS  PubMed  Google Scholar 

  13. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24(2):115–25.

    Article  PubMed  Google Scholar 

  14. Tsaitas C, Semertzidou A, Sinakos E. Update on inflammatory bowel disease in patients with primary sclerosing cholangitis. World J Hepatol. 2014;6(4):178–87.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Wade TP, Prasad CN, Virgo KS, Johnson FE. Experience with distal bile duct cancers in u.S. Veterans affairs hospitals: 1987–1991. J Surg Oncol. 1997;64(3):242–5.

    Article  CAS  PubMed  Google Scholar 

  16. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999;341(18):1368–78.

    Article  PubMed  Google Scholar 

  17. Jarnagin WR, Ruo L, Little SA, Klimstra D, D’Angelica M, DeMatteo RP, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98(8):1689–700.

    Article  PubMed  Google Scholar 

  18. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the conko-001 randomized trial. JAMA. 2013;310(14):1473–81.

    Article  CAS  PubMed  Google Scholar 

  19. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.

    Article  CAS  PubMed  Google Scholar 

  20. de Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29(23):3140–5.

    Article  PubMed  Google Scholar 

  21. Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934–40.

    Article  PubMed  Google Scholar 

  22. Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, et al. Swog s0809: a phase ii intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33(24):2617–22.

    Article  CAS  PubMed  Google Scholar 

  23. Iwatsuki S, Todo S, Marsh JW, Madariaga JR, Lee RG, Dvorchik I, et al. Treatment of hilar cholangiocarcinoma (klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg. 1998;187(4):358–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. De Vreede I, Steers JL, Burch PA, Rosen CB, Gunderson LL, Haddock MG, et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl. 2000;6(3):309–16.

    Article  PubMed  Google Scholar 

  25. Gu J, Bai J, Shi X, Zhou J, Qiu Y, Wu Y, et al. Efficacy and safety of liver transplantation in patients with cholangiocarcinoma: a systematic review and meta-analysis. Int J Cancer. 2012;130(9):2155–63.

    Article  CAS  PubMed  Google Scholar 

  26. Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 us centers. Gastroenterology. 2012;143(1):88–98 e83; quiz e14.

    Article  PubMed  Google Scholar 

  27. Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005;242(3):451–8; discussion 458–461.

    PubMed  PubMed Central  Google Scholar 

  28. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.

    Article  CAS  PubMed  Google Scholar 

  29. He S, Shen J, Sun X, Liu L, Dong J. A phase ii folfox-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin. J Chemother. 2014;26(4):243–7.

    Article  CAS  PubMed  Google Scholar 

  30. Paule B, Herelle MO, Rage E, Ducreux M, Adam R, Guettier C, et al. Cetuximab plus gemcitabine-oxaliplatin (gemox) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology. 2007;72(1–2):105–10.

    Article  CAS  PubMed  Google Scholar 

  31. Suzuki E, Ikeda M, Okusaka T, Nakamori S, Ohkawa S, Nagakawa T, et al. A multicenter phase ii study of s-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother Pharmacol. 2013;71(5):1141–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Bridgewater J, Palmer D, Cunningham D, Iveson T, Gillmore R, Waters J, et al. Outcome of second-line chemotherapy for biliary tract cancer. Eur J Cancer. 2013;49(6):1511.

    Article  CAS  PubMed  Google Scholar 

  33. Croitoru A, Gramaticu I, Dinu I, Gheorghe L, Alexandrescu S, Buica F, et al. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma – a retrospective study. J Gastrointest Liver Dis: JGLD. 2012;21(3):277–84.

    Google Scholar 

  34. Fornaro L, Vivaldi C, Cereda S, Leone F, Aprile G, Lonardi S, et al. Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. J Exp Clin Cancer Res: CR. 2015;34(1):156.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Sasaki T, Isayama H, Nakai Y, Takahara N, Satoh Y, Takai D, et al. A pilot study of salvage irinotecan monotherapy for advanced biliary tract cancer. Anticancer Res. 2013;33(6):2619–22.

    CAS  PubMed  Google Scholar 

  36. Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, et al. Multi-institutional phase ii study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011;29(17):2357–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Peck J, Wei L, Zalupski M, O’Neil B, Villalona Calero M, Bekaii-Saab T. Her2/neu may not be an interesting target in biliary cancers: results of an early phase ii study with lapatinib. Oncology. 2012;82(3):175–9.

    Article  CAS  PubMed  Google Scholar 

  38. Finn RS, Ahn DH, Javle MM, Tan BR Jr, Weekes CD, Bendell JC, Patnaik A, Khan GN, Laheru D, Chavira R, Christy-Bittel J, Barrett E, Sawyer MB, Bekaii-Saab TS. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. Invest New Drugs. 2018;36(6):1037–43. https://doi.org/10.1007/s10637-018-0600-2. Epub 2018 May 22.

    Article  CAS  PubMed  Google Scholar 

  39. Ahn DH, Li J, Wei L, Doyle A, Marshall JL, Schaaf LJ, et al. Results of an abbreviated phase-ii study with the akt inhibitor mk-2206 in patients with advanced biliary cancer. Sci Rep. 2015;5:12122.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, et al. A phase ii study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009;64(4):777–83.

    Article  CAS  PubMed  Google Scholar 

  41. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, et al. Phase ii study of erlotinib in patients with advanced biliary cancer. J Clin Oncol. 2006;24(19):3069–74.

    Article  CAS  PubMed  Google Scholar 

  42. Lubner SJ, Mahoney MR, Kolesar JL, Loconte NK, Kim GP, Pitot HC, et al. Report of a multicenter phase ii trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase ii consortium study. J Clin Oncol. 2010;28(21):3491–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. El-Khoueiry AB, Rankin C, Siegel AB, Iqbal S, Gong IY, Micetich KC, et al. S0941: a phase 2 swog study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer. 2014;110(4):882–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. El-Khoueiry AB, Rankin CJ, Ben-Josef E, Lenz HJ, Gold PJ, Hamilton RD, et al. Swog 0514: a phase ii study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs. 2012;30(4):1646–51.

    Article  CAS  PubMed  Google Scholar 

  45. Bengala C, Bertolini F, Malavasi N, Boni C, Aitini E, Dealis C, et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase ii trial. Br J Cancer. 2010;102(1):68–72.

    Article  CAS  PubMed  Google Scholar 

  46. Yi JH, Thongprasert S, Lee J, Doval DC, Park SH, Park JO, et al. A phase ii study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study. Eur J Cancer. 2012;48(2):196–201.

    Article  CAS  PubMed  Google Scholar 

  47. Buzzoni R, Pusceddu S, Bajetta E, De Braud F, Platania M, Iannacone C, et al. Activity and safety of rad001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase ii itmo study. Ann Oncol. 2014;25(8):1597–603.

    Article  CAS  PubMed  Google Scholar 

  48. Santoro A, Gebbia V, Pressiani T, Testa A, Personeni N, Arrivas Bajardi E, et al. A randomized, multicenter, phase ii study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the vangogh study. Ann Oncol. 2015;26(3):542–7.

    Article  CAS  PubMed  Google Scholar 

  49. Goel HL, Mercurio AM. Vegf targets the tumour cell. Nat Rev Cancer. 2013;13(12):871–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Quan ZW, Wu K, Wang J, Shi W, Zhang Z, Merrell RC. Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer. J Am Coll Surg. 2001;193(4):380–3.

    Article  CAS  PubMed  Google Scholar 

  51. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, et al. Phase i safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19(3):843–50.

    Article  CAS  PubMed  Google Scholar 

  52. Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, et al. Phase ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 2001;19(3):851–6.

    Article  CAS  PubMed  Google Scholar 

  53. Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose pet with clinical outcome: a phase 2 study. Lancet Oncol. 2010;11(1):48–54.

    Article  CAS  PubMed  Google Scholar 

  54. Benckert C, Jonas S, Cramer T, Von Marschall Z, Schafer G, Peters M, et al. Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res. 2003;63(5):1083–92.

    CAS  PubMed  Google Scholar 

  55. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, et al. Azd2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005;65(10):4389–400.

    Article  CAS  PubMed  Google Scholar 

  56. Lee JK, Capanu M, O’Reilly EM, Ma J, Chou JF, Shia J, et al. A phase ii study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. Br J Cancer. 2013;109(4):915–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Moehler M, Maderer A, Schimanski C, Kanzler S, Denzer U, Kolligs FT, et al. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase ii aio study with biomarker and serum programme. Eur J Cancer. 2014;50(18):3125–35.

    Article  CAS  PubMed  Google Scholar 

  58. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (London, England). 2006;368(9544):1329–38.

    Article  CAS  Google Scholar 

  59. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (abc-03): a randomised phase 2 trial. Lancet Oncol. 2015;16(8):967–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Xu L, Hausmann M, Dietmaier W, Kellermeier S, Pesch T, Stieber-Gunckel M, et al. Expression of growth factor receptors and targeting of egfr in cholangiocarcinoma cell lines. BMC Cancer. 2010;10:302.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Yoon JH, Gwak GY, Lee HS, Bronk SF, Werneburg NW, Gores GJ. Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol. 2004;41(5):808–14.

    Article  CAS  PubMed  Google Scholar 

  63. Kaufman M, Mehrotra B, Limaye S, White S, Fuchs A, Lebowicz Y, et al. Egfr expression in gallbladder carcinoma in north america. Int J Med Sci. 2008;5(5):285–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, et al. Clinicopathological and prognostic significance of egfr, vegf, and her2 expression in cholangiocarcinoma. Br J Cancer. 2008;98(2):418–25.

    Article  CAS  PubMed  Google Scholar 

  65. Zhou YM, Li YM, Cao N, Feng Y, Zeng F. Significance of expression of epidermal growth factor (egf) and its receptor (egfr) in chronic cholecystitis and gallbladder carcinoma. Ai zheng = Aizheng =Chin J Cancer. 2003;22(3):262–5.

    CAS  Google Scholar 

  66. Yoshikawa D, Ojima H, Kokubu A, Ochiya T, Kasai S, Hirohashi S, et al. Vandetanib (zd6474), an inhibitor of vegfr and egfr signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer. 2009;100(8):1257–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012;13(2):181–8.

    Article  CAS  PubMed  Google Scholar 

  68. Gruenberger B, Schueller J, Heubrandtner U, Wrba F, Tamandl D, Kaczirek K, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol. 2010;11(12):1142–8.

    Article  CAS  PubMed  Google Scholar 

  69. Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardiere C, Boucher E, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (bingo): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15(8):819–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-folfox4 treatment and ras mutations in colorectal cancer. N Engl J Med. 2013;369(11):1023–34.

    Article  CAS  PubMed  Google Scholar 

  71. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. Folfiri plus cetuximab versus folfiri plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (fire-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–75.

    Article  CAS  PubMed  Google Scholar 

  72. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, et al. Peak: A randomized, multicenter phase ii study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mfolfox6) or bevacizumab plus mfolfox6 in patients with previously untreated, unresectable, wild-type kras exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32(21):2240–7.

    Article  CAS  PubMed  Google Scholar 

  73. Tadlock L, Yamagiwa Y, Marienfeld C, Patel T. Double-stranded rna activates a p38 mapk-dependent cell survival program in biliary epithelia. Am J Physiol Gastrointest Liver Physiol. 2003;284(6):G924–32.

    Article  CAS  PubMed  Google Scholar 

  74. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, et al. Mutations of the braf gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut. 2003;52(5):706–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Finn RSJM, Tan BR, Weekes CD, et al. A phase i study of mek inhibitor mek162 (arry-438162) in patients with biliary tract cancer. J Clin Oncol. 2012;30:4s.. (suppl; abstr 220).

    Article  Google Scholar 

  76. Schmitz KJ, Lang H, Wohlschlaeger J, Sotiropoulos GC, Reis H, Schmid KW, et al. Akt and erk1/2 signaling in intrahepatic cholangiocarcinoma. World J Gastroenterol. 2007;13(48):6470–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Chung JY, Hong SM, Choi BY, Cho H, Yu E, Hewitt SM. The expression of phospho-akt, phospho-mtor, and pten in extrahepatic cholangiocarcinoma. Clin Cancer Res. 2009;15(2):660–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Deshpande V, Nduaguba A, Zimmerman SM, Kehoe SM, Macconaill LE, Lauwers GY, et al. Mutational profiling reveals pik3ca mutations in gallbladder carcinoma. BMC Cancer. 2011;11:60.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Li Q, Yang Z. Expression of phospho-erk1/2 and pi3-k in benign and malignant gallbladder lesions and its clinical and pathological correlations. J Exp Clin Cancer Res: CR. 2009;28:65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Tanno S, Yanagawa N, Habiro A, Koizumi K, Nakano Y, Osanai M, et al. Serine/threonine kinase akt is frequently activated in human bile duct cancer and is associated with increased radioresistance. Cancer Res. 2004;64(10):3486–90.

    Article  CAS  PubMed  Google Scholar 

  81. Yoon H, Min JK, Lee JW, Kim DG, Hong HJ. Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of akt and extracellular signal-regulated kinase (erk)1/2. Biochem Biophys Res Commun. 2011;405(3):333–7.

    Article  CAS  PubMed  Google Scholar 

  82. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for her2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of her2-positive advanced gastric or gastro-oesophageal junction cancer (toga): a phase 3, open-label, randomised controlled trial. Lancet (London, England). 2010;376(9742):687–97.

    Article  CAS  Google Scholar 

  84. Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jager E, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by her2 status: a european and USA international collaborative analysis. Ann Oncol. 2012;23(10):2656–62.

    Article  CAS  PubMed  Google Scholar 

  85. Kim HJ, Yoo TW, Park DI, Park JH, Cho YK, Sohn CI, et al. Gene amplification and protein overexpression of her-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients. Ann Oncol. 2007;18(5):892–7.

    Article  CAS  PubMed  Google Scholar 

  86. Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, et al. Targeting egfr/her2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer. 2010;10:631.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Javle M, Churi C, Kang HC, Shroff R, Janku F, Surapaneni R, et al. Her2/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015;8:58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Kawamoto T, Ishige K, Thomas M, Yamashita-Kashima Y, Shu S, Ishikura N, et al. Overexpression and gene amplification of egfr, her2, and her3 in biliary tract carcinomas, and the possibility for therapy with the her2-targeting antibody pertuzumab. J Gastroenterol. 2015;50(4):467–79.

    Article  CAS  PubMed  Google Scholar 

  89. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, et al. Analysis of braf v600e mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121(3):397–405.

    Article  CAS  PubMed  Google Scholar 

  90. Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS. Braf(e600) in benign and malignant human tumours. Oncogene. 2008;27(7):877–95.

    Article  CAS  PubMed  Google Scholar 

  91. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, et al. Braf and ras mutations in human lung cancer and melanoma. Cancer Res. 2002;62(23):6997–7000.

    CAS  PubMed  Google Scholar 

  92. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the braf gene in human cancer. Nature. 2002;417(6892):949–54.

    Article  CAS  PubMed  Google Scholar 

  93. Goeppert B, Frauenschuh L, Renner M, Roessler S, Stenzinger A, Klauschen F, et al. Braf v600e-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. Mod Pathol. 2014;27(7):1028–34.

    Article  CAS  PubMed  Google Scholar 

  94. Robertson S, Hyder O, Dodson R, Nayar SK, Poling J, Beierl K, et al. The frequency of kras and braf mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome. Hum Pathol. 2013;44(12):2768–73.

    Article  CAS  PubMed  Google Scholar 

  95. Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring braf(v600e) mutation. Thyroid. 2013;23(10):1277–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. Braf inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012;366(21):2038–40.

    Article  PubMed  Google Scholar 

  97. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in braf-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (London, England). 2012;380(9839):358–65.

    Article  CAS  Google Scholar 

  98. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in braf v600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, et al. Mutant idh inhibits hnf-4alpha to block hepatocyte differentiation and promote biliary cancer. Nature. 2014;513(7516):110–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Belov AA, Mohammadi M. Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb Perspect Biol. 2013;5(6):1–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in fgfr and egfr pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Ross JS, Wang K, Gay L, Al-Rohil R, Rand JV, Jones DM, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014;19(3):235–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Sia D, Losic B, Moeini A, Cabellos L, Hao K, Revill K, et al. Massive parallel sequencing uncovers actionable fgfr2-pphln1 fusion and araf mutations in intrahepatic cholangiocarcinoma. Nat Commun. 2015;6:6087.

    Article  CAS  PubMed  Google Scholar 

  104. Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59(4):1427–34.

    Article  CAS  PubMed  Google Scholar 

  105. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al. Identification of targetable fgfr gene fusions in diverse cancers. Cancer Discov. 2013;3(6):636–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Graham RP, Barr Fritcher EG, Pestova E, Schulz J, Sitailo LA, Vasmatzis G, et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol. 2014;45(8):1630–8.

    Article  CAS  PubMed  Google Scholar 

  107. Kouhara H, Hadari YR, Spivak-Kroizman T, Schilling J, Bar-Sagi D, Lax I, et al. A lipid-anchored grb2-binding protein that links fgf-receptor activation to the ras/mapk signaling pathway. Cell. 1997;89(5):693–702.

    Article  CAS  PubMed  Google Scholar 

  108. Gu TL, Deng X, Huang F, Tucker M, Crosby K, Rimkunas V, et al. Survey of tyrosine kinase signaling reveals ros kinase fusions in human cholangiocarcinoma. PLoS One. 2011;6(1):e15640.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Saborowski A, Saborowski M, Davare MA, Druker BJ, Klimstra DS, Lowe SW. Mouse model of intrahepatic cholangiocarcinoma validates fig-ros as a potent fusion oncogene and therapeutic target. Proc Natl Acad Sci U S A. 2013;110(48):19513–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ros1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Zender S, Nickeleit I, Wuestefeld T, Sorensen I, Dauch D, Bozko P, et al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell. 2013;23(6):784–95.

    Article  CAS  PubMed  Google Scholar 

  112. Yoon HA, Noh MH, Kim BG, Han JS, Jang JS, Choi SR, et al. Clinicopathological significance of altered notch signaling in extrahepatic cholangiocarcinoma and gallbladder carcinoma. World J Gastroenterol. 2011;17(35):4023–30.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Wu WR, Shi XD, Zhang R, Zhu MS, Xu LB, Yu XH, et al. Clinicopathological significance of aberrant notch receptors in intrahepatic cholangiocarcinoma. Int J Clin Exp Pathol. 2014;7(6):3272–9.

    PubMed  PubMed Central  Google Scholar 

  114. Huntzicker EG, Hotzel K, Choy L, Che L, Ross J, Pau G, et al. Differential effects of targeting notch receptors in a mouse model of liver cancer. Hepatology. 2015;61(3):942–52.

    Article  CAS  PubMed  Google Scholar 

  115. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. Pd-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Medical Oncology, Mayo Clinic, Phoenix, AZ, USA

    Daniel H. Ahn & Tanios Bekaii-Saab

Authors
  1. Daniel H. Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tanios Bekaii-Saab
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tanios Bekaii-Saab .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Hacettepe University Institute of Cancer, Sihhiye, Ankara, Turkey

    Suayib Yalcin

  2. Department of Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA

    Philip A. Philip

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ahn, D.H., Bekaii-Saab, T. (2019). Cholangiocarcinoma. In: Yalcin, S., Philip, P. (eds) Textbook of Gastrointestinal Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-18890-0_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-18890-0_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-18888-7

  • Online ISBN: 978-3-030-18890-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation